<DOC>
	<DOCNO>NCT00005807</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness BMS-247550 treating patient metastatic , recurrent , locally advanced , ovarian cancer , breast cancer , metastatic unresectable solid tumor .</brief_summary>
	<brief_title>BMS-247550 Treating Patients With Advanced Solid Tumors , Breast Cancer Recurrent Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose , recommend phase II dose , associate toxic effect BMS-247550 patient advance solid tumor . - Determine pharmacokinetic pharmacodynamic relationship treatment regimen patient . - Assess extent microtubule bundle mitotic aster formation cell cycle kinetics peripheral blood mononuclear cell patient treat regimen . - Determine evidence antitumor activity treatment regimen patient . - Evaluate relationship tumor response occurrence mutation class 1 isotype B-tubulin B-tubulin isotype distribution patient advance recurrent solid tumor , ovarian cancer , breast cancer treat regimen . - Investigate MDR1 , MRP , cMOAT mRNA protein expression prognosticator tumor response patient treat regimen . - Determine relationship stathmin expression phosphorylation status function response patient treat regimen . - Correlate expression proapoptotic ( p53 , bax , bad , bid ) antiapoptotic ( survivin , inhibitor apoptotic protein , bcl-2 , bcl-x ) proteins tumor sample and/or ascites response clinical outcome patient treat regimen . OUTLINE : This dose-escalation , multicenter study . - Part I : Patients advance solid tumor receive BMS-247550 IV 1 hour every 3 week . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos BMS-247550 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Part II : Patients ovarian , breast , cancer receive BMS-247550 part I portion study MTD . Treatment continue absence disease progression unacceptable toxicity . Patients follow 2 month . PROJECTED ACCRUAL : Approximately 42-66 patient accrue study within 12-16 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Part I : Histologically cytologically confirm metastatic unresectable solid malignancy standard curative therapy exist longer effective Part II : Metastatic , recurrent , locally advance breast , ovarian , cancer At least 1 site amenable biopsy No known brain metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Male female Menopausal status : Not specify Performance status : ECOG 01 OR Karnofsky 80100 % Life expectancy : Not specify Hematopoietic : Hemoglobin least 9.0 g/dL WBC least 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin normal AST/ALT great 3 time upper limit normal Gilbert 's syndrome allow Renal : Creatinine great 2 mg/dL Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other : No grade 2 great clinical neuropathy No prior allergy hypersensitivity reaction ( grade 2 great ) prior paclitaxel therapy contain Cremophor EL No allergy intolerance steroid , diphenhydramine , cimetidine , ranitidine No uncontrolled concurrent illness No active infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy No prior radiotherapy 35 % bone marrow Prior whole pelvic radiotherapy allow Surgery : See Disease Characteristics Other : No concurrent anticancer therapies commercial agent No concurrent investigational agent No concurrent highly active antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2003</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>ovarian stromal cancer</keyword>
	<keyword>stage III ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>borderline ovarian surface epithelial-stromal tumor</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>male breast cancer</keyword>
</DOC>